Last week's news out of WashU Medicine described a personalized vaccine that, in an early trial at Siteman Cancer Center, appeared to slow tumor progression in patients with glioblastoma, the brain cancer with the bleakest prognosis in adult oncology. The trial participants showed a measurable immune response to a treatment designed around the specific mutations in their own tumors. That last clause is doing enormous work. The idea that you could read a tumor's genetic signature and then build a drug, or now a vaccine, around it sounds like the obvious move in 2026. In 1959, when a researcher in Philadelphia squinted at a stained cell and noticed that one chromosome looked shorter than it should, it was the opposite of obvious. The line from that microscope to a WashU press release runs more than sixty years, and most of the interesting decisions happened in the middle.
Coverage of the WashU trial has done a competent job explaining what the vaccine does. What it skips is the question of how anyone ever convinced the field, the FDA, and a pharmaceutical company that treating cancer by its specific molecular defect was a serious clinical strategy. The vocabulary now sits in feature stories without much friction: targeted therapy, tumor-specific antigen, neoantigen vaccine. Each of those phrases carries a methodological argument inside it, and that argument had to be won, slowly, against a research culture that for decades treated cancer as one disease to be carpet-bombed with cytotoxins. The method came before the headline. To understand why a personalized brain cancer vaccine is plausible enough to fund and run, look at the first time someone pulled this trick off.
Jessica Wapner's The Philadelphia Chromosome reconstructs that first time. The story begins with David Hungerford and Peter Nowell noticing, in 1959, that cells from patients with chronic myeloid leukemia carried a shortened chromosome 22. For more than a decade, no one knew what to do with the observation. It was a finding in search of a mechanism, and Wapner spends real time in the quiet years, when the chromosome was a curiosity passed between cytogeneticists. The mechanism arrived in pieces.
Janet Rowley identified the abnormality as a translocation between chromosomes 9 and 22 in the early 1970s. Later work showed that the swap fused two genes, BCR and ABL, into a hybrid that produced a permanently switched-on enzyme driving white blood cells to multiply. Wapner walks through this biology without softening it. You finish the chapter understanding what a tyrosine kinase actually does, which is more than most science journalism is willing to ask of you. The back half of the book follows the drug.
Brian Druker, then a relatively junior oncologist, championed a compound from Ciba-Geigy (later Novartis) called STI-571, which blocked the BCR-ABL enzyme in the lab. The internal corporate skepticism is one of the better threads here. CML was considered too small a market to justify development costs, and Druker spent years pushing a reluctant company toward a clinical trial that produced Gleevec, approved by the FDA in 2001 with response rates that startled the field. Wapner draws on more than thirty-five interviews, and the patient voices keep the science from floating off into abstraction. Suzan McNamara, a Canadian CML patient who organized an online petition to accelerate Gleevec's availability, gets her own arc. So do the early trial volunteers who lived long enough to develop resistance mutations, which then produced second-generation drugs. The book is honest about this loop: a targeted therapy creates evolutionary pressure on the tumor, and the tumor answers. The book has a weakness worth naming. Wapner treats Gleevec as a template more cleanly than later history has borne out. CML turned out to be unusually tractable, with one driver mutation in a slow-growing cancer of accessible cells. Most solid tumors, glioblastoma very much included, are messier, with multiple drivers, heterogeneous cell populations, and barriers like the blood-brain interface. Wapner gestures at this, but coming to the book in 2026, you have to hold the triumph and the caveat together yourself.
When the glioblastoma news catches your attention again this year, and it will, Wapner's book is good company for the next round of coverage. What is the specific molecular target. How was it identified. Who is funding the trial, and who almost did not. What happens when the tumor evolves around the treatment. These are the questions the Philadelphia chromosome story trained an entire generation of oncologists to ask, and they remain the most honest way to tell whether a promising headline is the beginning of something or a footnote in someone else's eventual breakthrough.